HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- (alpha- methyl- 4- bromobenzylamino)phosphonomethyl- 1,4- dihydroquinoxaline- 2,3- dione

an excitatory amino acid antagonist; structure in first source

Also Known As:

(1RS,1'S)-PEAQX; NVP-AAM077; PEAQX cpd

Networked: 10 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinoxalines: 324
      - 5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione: 10

Experts

1.	Wang, Minyan: 2 articles (10/2018 - 01/2012)
2.	Hou, Xusheng: 1 article (03/2021)
3.	Liang, Yanling: 1 article (03/2021)
4.	Ma, Yuxin: 1 article (03/2021)
5.	Nie, Lei: 1 article (03/2021)
6.	Tian, Yinghong: 1 article (03/2021)
7.	Wang, Jieqin: 1 article (03/2021)
8.	Wu, Wenyu: 1 article (03/2021)
9.	Zhang, Xingmei: 1 article (03/2021)
10.	Du, Hongyin: 1 article (11/2018)

Related Diseases

1.	Ischemia 11/01/2008 - "NR2A subtype-specific antagonist NVP-AAM077 enhanced neuronal death after transient global ischemia and abolished the induction of ischemic tolerance. " 08/01/2010 - "Activating NR2A using bicuculline and 4-aminopiridine induced resistance to lethal ischemia accompanied by elevated CRE activity levels, and this effect was abolished by NVP-AAM077. "
2.	Hyperalgesia 03/01/2021 - "We used a rat model of spared nerve injury (SNI) and demonstrated that the intrathecal administration of the NR2A-selective antagonist NVP-AAM077 and the NR2B-selective antagonist Ro25-6981 prevented and reversed mechanical allodynia following SNI. " 03/01/2021 - "Administration of exogenous leptin mimicked SNI-induced behavioral allodynia, which was also prevented by NVP-AAM077 and Ro25-6981. " 07/01/2007 - "pretreatment of mice with NVP-AAM077 [[(R)-[(S)-1-(4-bromophenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid] (selective antagonist of the NR2A subunit of the NMDAR) or DT-3 [H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Leu-Arg-Lys-Lys-Lys-Lys-Lys-His-OH] (inhibitor of protein kinase G) had no effect on (S)-3,5-DHPG-mediated hyperalgesia. "
3.	Cognitive Dysfunction 11/01/2018 - "Inhibition of Src and NR2A with PP2 and NVP-AAM077 respectively not only down-regulated the levels of p-Src and p-NR2A, but also ameliorated hippocampal neurons apoptosis and long-term cognitive impairment after HIR. "
4.	Dyskinesias (Dyskinesia) 05/15/2013 - "NVP-AAM077 failed to prevent dyskinesia while Ro 25-6981 mildly attenuated it. " 05/15/2013 - "To investigate whether GluN2A and GluN2B NMDA receptor subunits are involved in motor pathways underlying dyskinesia expression, systemic NVP-AAM077 and Ro 25-6981 were tested for their ability to attenuate levodopa-induced abnormal involuntary movements. "
5.	Shock 02/01/2008 - "To do so, we infused the NR1/NR2B receptor antagonist CP101,606 (0.5, 1.5, or 4.5 microg/amygdala) or the NR1/NR2A-preferring antagonist NVP-AAM077 (0.075, 0.25, 0.75, or 2.5 microg/amygdala) into the amygdala prior to either fear conditioning (i.e., light-shock pairings) or fear-potentiated startle testing. "

Related Drugs and Biologics

1.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
2.	Leptin
3.	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)
4.	Phosphotransferases (Kinase)
5.	Levodopa (L Dopa)
6.	Enzymes
7.	Bicuculline
8.	arginyl-glutamine
9.	phosphonic acid
10.	Ro 25-6981